135 related articles for article (PubMed ID: 1378640)
1. Comparison of Iloprost, Cicaprost and prostacyclin effects on cyclic AMP metabolism in intact platelets.
Ashby B
Prostaglandins; 1992 Mar; 43(3):255-61. PubMed ID: 1378640
[TBL] [Abstract][Full Text] [Related]
2. Functional and ligand binding studies suggest heterogeneity of platelet prostacyclin receptors.
Armstrong RA; Lawrence RA; Jones RL; Wilson NH; Collier A
Br J Pharmacol; 1989 Jul; 97(3):657-68. PubMed ID: 2474350
[TBL] [Abstract][Full Text] [Related]
3. Novel mechanism of heterologous desensitization of adenylate cyclase: prostaglandins bind with different affinities to both stimulatory and inhibitory receptors on platelets.
Ashby B
Mol Pharmacol; 1990 Jul; 38(1):46-53. PubMed ID: 1695318
[TBL] [Abstract][Full Text] [Related]
4. Model of prostaglandin-regulated cyclic AMP metabolism in intact platelets: examination of time-dependent effects on adenylate cyclase and phosphodiesterase activities.
Ashby B
Mol Pharmacol; 1989 Dec; 36(6):866-73. PubMed ID: 2481225
[TBL] [Abstract][Full Text] [Related]
5. Cyclic AMP turnover in response to prostaglandins in intact platelets: evidence for separate stimulatory and inhibitory prostaglandin receptors.
Ashby B
Second Messengers Phosphoproteins; 1988; 12(1):45-57. PubMed ID: 2848122
[TBL] [Abstract][Full Text] [Related]
6. Octimibate, a potent non-prostanoid inhibitor of platelet aggregation, acts via the prostacyclin receptor.
Merritt JE; Hallam TJ; Brown AM; Boyfield I; Cooper DG; Hickey DM; Jaxa-Chamiec AA; Kaumann AJ; Keen M; Kelly E
Br J Pharmacol; 1991 Jan; 102(1):251-9. PubMed ID: 1710526
[TBL] [Abstract][Full Text] [Related]
7. Effects of heparin on prostacyclin binding and platelet adenylate cyclase activity stimulated by iloprost and forskolin.
Jaschonek K; Faul C; Daiss W; Weisenberger H
Prostaglandins Leukot Med; 1986 Oct; 24(2-3):199-206. PubMed ID: 2432618
[TBL] [Abstract][Full Text] [Related]
8. Platelet receptor desensitization induced by elevated prostacyclin levels causes platelet-endothelial cell adhesion.
Darius H; Binz C; Veit K; Fisch A; Meyer J
J Am Coll Cardiol; 1995 Sep; 26(3):800-6. PubMed ID: 7543911
[TBL] [Abstract][Full Text] [Related]
9. Prostaglandin endoperoxide analogues which are both thromboxane receptor antagonists and prostacyclin mimetics.
Armstrong RA; Jones RL; MacDermot J; Wilson NH
Br J Pharmacol; 1986 Mar; 87(3):543-51. PubMed ID: 3026540
[TBL] [Abstract][Full Text] [Related]
10. Comparison of vasodilatory prostaglandins with respect to cAMP-mediated phosphorylation of a target substrate in intact human platelets.
Nolte C; Eigenthaler M; Schanzenbächer P; Walter U
Biochem Pharmacol; 1991 Jul; 42(2):253-62. PubMed ID: 1713458
[TBL] [Abstract][Full Text] [Related]
11. Synergistic interaction of adenylate cyclase activators and nitric oxide donor SIN-1 on platelet cyclic AMP.
Fisch A; Michael-Hepp J; Meyer J; Darius H
Eur J Pharmacol; 1995 May; 289(3):455-61. PubMed ID: 7556414
[TBL] [Abstract][Full Text] [Related]
12. Prostacyclin (PGI) receptor binding and cyclic AMP synthesis activities of PGI1 analogues, SM-10906 and its methyl ester, SM-10902, in mastocytoma P-815 cells.
Oka M; Negishi M; Yamamoto T; Satoh K; Hirohashi T; Ichikawa A
Biol Pharm Bull; 1994 Jan; 17(1):74-7. PubMed ID: 7511960
[TBL] [Abstract][Full Text] [Related]
13. Prostacyclin analogues inhibit tissue factor expression in the human monocytic cell line THP-1 via a cyclic AMP-dependent mechanism.
Crutchley DJ; Solomon DE; Conanan LB
Arterioscler Thromb; 1992 Jun; 12(6):664-70. PubMed ID: 1375507
[TBL] [Abstract][Full Text] [Related]
14. Comparison of anti-aggregatory effects of PGI2, PGI3 and iloprost on human and rabbit platelets.
Kobzar G; Mardla V; Järving I; Samel N
Cell Physiol Biochem; 2001; 11(5):279-84. PubMed ID: 11684817
[TBL] [Abstract][Full Text] [Related]
15. Effects of TRK-100, a stable prostacyclin analogue, on regulation of cyclic AMP metabolism in platelets.
Nogimori K; Kajikawa N; Nishio S; Yajima M
Prostaglandins; 1989 Feb; 37(2):205-12. PubMed ID: 2543034
[TBL] [Abstract][Full Text] [Related]
16. Biochemical and pharmacological activity of arene-fused prostacyclin analogues on human platelets.
Jakubowski JA; Utterback BG; Mais DE; Hardinger SA; Braish TF; Nevill CR; Fuchs PL
Prostaglandins; 1994 Mar; 47(3):189-201. PubMed ID: 8016389
[TBL] [Abstract][Full Text] [Related]
17. Comparison of equimolar concentrations of iloprost, prostacyclin, and prostaglandin E1 on human platelet function.
Fisher CA; Kappa JR; Sinha AK; Cottrell ED; Reiser HJ; Addonizio VP
J Lab Clin Med; 1987 Feb; 109(2):184-90. PubMed ID: 2433373
[TBL] [Abstract][Full Text] [Related]
18. Desensitization of platelets to iloprost. Loss of specific binding sites and heterologous desensitization of adenylate cyclase.
Jaschonek K; Faul C; Schmidt H; Renn W
Eur J Pharmacol; 1988 Mar; 147(2):187-96. PubMed ID: 2452749
[TBL] [Abstract][Full Text] [Related]
19. Prostaglandin E2 both stimulates and inhibits adenyl cyclase on platelets: comparison of effects on cloned EP4 and EP3 prostaglandin receptor subtypes.
Mao GF; Jin JG; Bastepe M; Ortiz-Vega S; Ashby B
Prostaglandins; 1996 Sep; 52(3):175-85. PubMed ID: 8908618
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of TPA and 12(S)-HETE-stimulated tumor cell adhesion by prostacyclin and its stable analogs: rationale for their antimetastatic effects.
Tang DG; Grossi IM; Tang KQ; Diglio CA; Honn KV
Int J Cancer; 1995 Jan; 60(3):418-25. PubMed ID: 7530235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
